Table 3.
Result of the Measurement of IGFBP7 for the Diagnosis of EJA
| IGFBP7 | AUC | SEN, % | SPE, % | FPS, % | FNS, % | PPV, % | NPV, % | PLR | NLR |
|---|---|---|---|---|---|---|---|---|---|
| EJA vs NC | 0.794 (0.733–0.854) |
63.3 (54.0–71.8) |
90.9 (82.4–95.7) |
9.5 (4.5–18.4) |
35.4 (27.2–44.6) |
90.5 (81.6–95.5) |
64.5 (55.4–72.8) |
6.97 (3.55–13.7) |
0.40 (0.32–0.51) |
| Early-stage EJA vs NC | 0.749 (0.644–0.854) |
54.3 (36.9–70.8) |
90.9 (82.4–95.7) |
29.6 (14.5–50.3) |
16.7 (10.1–26.0) |
70.4 (49.7–85.5) |
83.3 (74.0–89.9) |
5.97 (2.89–12.4) |
0.50 (0.35–0.72) |
Numbers in brackets represent the 95% confidence interval.
IGFBP7, insulin-like growth factor binding protein 7; EJA, esophagogastric junction adenocarcinoma; NC, normal controls; AUC, area under the receiver operating characteristic curve; SEN, sensitivity; SPE, specificity; FPS, false-positive rate; FNS, false-negative rate; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio.